A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)

NCT02901431 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

339

Enrollment

INDUSTRY

Sponsor class

Stopped The 24-week analysis indicated no clinical or statistical benefit for the primary endpoint for the overall study population. No new safety concerns identified.

Conditions

Autism Spectrum Disorder

Interventions

DRUG: Placebo
DRUG: RO5285119

Sponsor

Hoffmann-La Roche